Media Coverage

Read about BostonGene in the news.

Year

2026

BostonGene, Daiichi Sankyo advance ADC development with AI insights

Daiichi Sankyo tapped BostonGene's AI-based translational analysis platform

2026

Can AI improve clinical drug development as much as it has preclinical research?

Can AI genuinely reshape the cost, time, and high failure rates inherent to drug development

2026

Friday Five: Another pharma taps BostonGene’s twin modelling approach; and more

BostonGene has added Daiichi Sankyo to its growing list of pharma partners

2025

BostonGene: Transforming Cancer Drug Discovery and Development With AI Multiomics

Today, bringing a new cancer drug to market takes an average of 10.5 years, costs more than $2.5 billion, and succeeds only 8% of the time

Testimonials

Through BostonGene, we are utilizing multiparametric discovery and big data analytics to uncover and validate biomarkers of therapeutic response.

Funda Meric-Bernstam, MD

Chair of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center

We look forward to using BostonGene’s technology to facilitate our work in mechanisms of cancer neoantigen recognition.

Gerald Linette, MD, PhD

Clinical Director of the Parker Institute for Cancer Immunotherapy, University of Pennsylvania

Together, we are working to identify novel biomarkers and develop next-generation therapies fora true personalized approach to cancer care.

David Ting, MD

Associate Clinical Director of Innovation, Massachusetts General Hospital

A tumor ‘‘personality’’ test: the BostonGene Tumor Portrait serves as a roadmap to guide treatment decision-making.

Christina Curtis, PhD, MSc

Director of Artificial Intelligence and Cancer Genomics and Breast Cancer Translational Research Stanford University

Through this collaboration we look forward to utilizing data and AI to gain more insights into the biology and mechanisms of investigational therapies at the earliest stages. These data will help us to better understand their potential in certain patient populations and ultimately help advance oncology medicines for patients who need them.

PK Morrow, MD

Head, Oncology Therapeutic Area Unit, Takeda

BostonGene's integrated analytic and AI capabilities will provide us with crucial insights towards developing breakthrough cancer treatments.

Stephen Slocum, PhD

Director of Drug Development, LigoChem

Collaborating with BostonGene allows us to apply advanced omnimodal analytics to real-world clinical challenges. By integrating genomic, transcriptomic and immune data into a unified platform, we can identify the right patients for the right trials, uncover novel biomarkers...

Ola Landgren, MD, PhD

Director of the Sylvester Myeloma Institute and professor of medicine with the Miller School of Medicine